Occam Places CBO for Oncology Biotech Accent Therapeutics
In September 2018, Occam recruited David Brower as Chief Business Officer of Accent Therapeutics, a developer of biomarker-driven cancer medicines.
David has held a number of life science business development, strategy, and investing roles prior to joining Accent. Most recently, he led the business development function for Blueprint Medicines, where he completed various strategic transactions, including its seminal partnerships with Roche Pharmaceuticals, CStone Pharmaceuticals, and Alexion Pharmaceuticals. Prior to Blueprint Medicines, David was a member of Pfizer Pharmaceuticals’ Worldwide Business Development team, focusing on licensing and M&A transactions and business development strategy. David began his career as a healthcare trader and investor for Lehman Brothers and Barclays Capital.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.